Edgewise Therapeutics, Inc. (EWTX) Financials

EWTX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 479.7 million 31.6 million
March 31, 2026 518.5 million 25.3 million
Dec. 31, 2025 552.6 million 30.3 million
Sept. 30, 2025 583.5 million 24.8 million

EWTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -43.5 million 9.4 million
March 31, 2026 -42.8 million 8.7 million
Dec. 31, 2025 -38.4 million -24.9 million
Sept. 30, 2025 -34.9 million 8.1 million

EWTX Net Income

No data available :(

EWTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 460.7 million - 3.6 million
March 31, 2026 499.6 million 2.8 million 1.0 million
Dec. 31, 2025 530.1 million 3.0 million 1.0 million
Sept. 30, 2025 563.3 million 3.2 million 1.0 million

EWTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 107.7 million
March 31, 2026 107.1 million
Dec. 31, 2025 102.9 million
Sept. 30, 2025 105.5 million

EWTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 32000 47.5 million 14.4 million -
March 31, 2026 260000 42.7 million 11.5 million -
Dec. 31, 2025 183000 43.6 million 12.4 million -
Sept. 30, 2025 89000 37.5 million 9.4 million -

EWTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 590000
Dec. 31, 2025 - -
Sept. 30, 2025 - -

EWTX

Price: $44.17

52 week price:
12.30
48.40

Earnings Per Share: -1.84 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 74985

Market Capitalization: 4.8 billion

Links: